Printer-friendly versionPDF változat

The purpose of this study is to evaluate the efficacy of a polypill strategy containing aspirin (100 mg), ramipril (2.5, 5 or 10 mgs), and atorvastatin (40 mgs) compared with the standard of care (usual care according to the local clinical practices at each participating country) in secondary prevention of major cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal ischemic stroke, and urgent revascularization) in elderly patients with a recent myocardial infarction.

Disease: Cardiovascular disease

Study phase: III

ECRIN support role: Local pharmacovigilance

Study/trial status: Start-up phase

Actual trial start date: 17/05/2016

Expected patient number: 3206 patients

Sponsor: Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC)

Sponsor type: Academic

Principal investigator (PI): Valentín Fuster

Current participating countries